bluebird sinks after updating LentiGlobin timeline

bluebird bio Inc. (NASDAQ:BLUE) lost $10.80 (19%) to $44.64, touching a 52-week low of $43.51 in intraday trading Monday after disclosing that it does not plan to provide updated data for LentiGlobin BB305 gene therapy to treat beta-thalassemia or sickle cell disease (SCD) until the American Society of Hematology (ASH) meeting in December. The disclosure came in a slide deck ahead of a scheduled presentation on Tuesday at the JPMorgan Healthcare Conference in San Francisco.

The past two years, bluebird has presented LentiGlobin data at the European Hematology Association (EHA) meeting in June. ...